SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Gregory Everson, Curtis Cooper, Christophe Hézode, Mitchell L. Shiffman, Eric Yoshida, Teresita Beltran-Jaramillo, Pietro Andreone, Savino Bruno, Peter Ferenci, Stefan Zeuzem, Michael Brunda, Sophie Le Pogam, Isabel Nájera, Julian Zhou, Mercidita T. Navarro, Athina Voulgari, Nancy S. Shulman, Ellen S. Yetzer, DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4, Liver International, 2015, 35, 1
  2. 2
    David Joseph, Peter Rose, Natalja Strelkowa, Armin Schultz, Jeanette Garcia, Mabrouk Elgadi, Fenglei Huang, Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers, The Journal of Clinical Pharmacology, 2015, 55, 4
  3. 3
    John P. Sabo, Benjamin Lang, Mabrouk Elgadi, Fenglei Huang, Effect of the Hepatitis C Virus Protease Inhibitor Faldaprevir on the Pharmacokinetics of an Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel in Healthy Female Volunteers, Antimicrobial Agents and Chemotherapy, 2015, 59, 1, 514

    CrossRef

  4. 4
    Kosh Agarwal, Ashley Barnabas, Faldaprevir for the treatment of genotype-1 hepatitis C virus, Expert Review of Gastroenterology & Hepatology, 2015, 9, 3, 277

    CrossRef

  5. 5
    Daniel P Webster, Paul Klenerman, Geoffrey M Dusheiko, Hepatitis C, The Lancet, 2015, 385, 9973, 1124

    CrossRef

  6. 6
    Daniele Blasquez Olmedo, Samária Ali Cader, Luís Cristóvão Porto, IFN-λ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors, Journal of Medical Virology, 2015, 87, 10
  7. 7
    John P. Sabo, Jens Kort, Charles Ballow, Angela D.M. Kashuba, Manuel Haschke, Manuel Battegay, Birgit Girlich, Naitee Ting, Benjamin Lang, Wei Zhang, Curtis Cooper, Drané O'Brien, Eleanore Seibert, Tom S. Chan, Donald Tweedie, Yongmei Li, Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: In vitro and in vivo correlation, The Journal of Clinical Pharmacology, 2015, 55, 4
  8. 8
    E. Druyts, M. Lorenzi, K. Toor, K. Thorlund, E. J. Mills, Network meta-analysis of direct-acting antivirals in combination with peginterferon-ribavirin for previously untreated patients with hepatitis C genotype 1 infection, QJM, 2015, 108, 4, 299

    CrossRef

  9. 9
    Tamer Elbaz, Mohamed El-Kassas, Gamal Esmat, New era for management of chronic hepatitis C virus using direct antiviral agents: A review, Journal of Advanced Research, 2015, 6, 3, 301

    CrossRef

  10. 10
    Nicole M. Welch, Donald M. Jensen, Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C, Liver International, 2015, 35,
  11. 11
    Fenglei Huang, Viktoria Moschetti, Benjamin Lang, Atef Halabi, Marc Petersen-Sylla, Chan-Loi Yong, Mabrouk Elgadi, Pharmacokinetics, Safety, and Tolerability of Faldaprevir in Patients with Renal Impairment, Antimicrobial Agents and Chemotherapy, 2015, 59, 1, 251

    CrossRef

  12. 12
    Peter Ferenci, Tarik Asselah, Graham R. Foster, Stefan Zeuzem, Christoph Sarrazin, Christophe Moreno, Denis Ouzan, Marina Maevskaya, Filipe Calinas, Luis E. Morano, Javier Crespo, Jean-François Dufour, Marc Bourlière, Kosh Agarwal, Daniel Forton, Marcus Schuchmann, Elmar Zehnter, Shuhei Nishiguchi, Masao Omata, George Kukolj, Yakov Datsenko, Miguel Garcia, Joseph Scherer, Anne-Marie Quinson, Jerry O. Stern, STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection, Journal of Hepatology, 2015, 62, 6, 1246

    CrossRef

  13. 13
    Douglas Dieterich, Mark Nelson, Vicente Soriano, Keikawus Arastéh, Josep M. Guardiola, Jürgen K. Rockstroh, Sanjay Bhagani, Montserrat Laguno, Cristina Tural, Patrick Ingiliz, Mamta K. Jain, Jerry O. Stern, Montserrat Manero, Richard Vinisko, Jens Kort, STARTVerso4, AIDS, 2015, 1

    CrossRef

  14. 14
    Chisa Kuga, Hirayuki Enomoto, Nobuhiro Aizawa, Tomoyuki Takashima, Naoto Ikeda, Akio Ishii, Yoshiyuki Sakai, Yoshinori Iwata, Hironori Tanaka, Masaki Saito, Hiroko Iijma, Shuhei Nishiguchi, Anti-interferon-α neutralizing antibody induced telaprevir resistance under the interferon-α plus telaprevir treatment in vitro, Biochemical and Biophysical Research Communications, 2014, 454, 3, 453

    CrossRef

  15. 15
    Manogna Nookathota, Sandeep Mukherjee, Antiviral therapy for chronic hepatitis C in 2014, Expert Review of Clinical Pharmacology, 2014, 7, 4, 499

    CrossRef

  16. 16
    Maximilian David Schneider, Christoph Sarrazin, Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?, Antiviral Research, 2014, 105, 64

    CrossRef

  17. 17
    Linzhi Chen, Roger St. George, Stephen H. Norris, Yanping Mao, Elsy Philip, Li-Quan Wang, Diana Wu, Michael J. Potchoiba, Biotransformation and mass balance of faldaprevir, a hepatitis C NS3/NS4 protease inhibitor in rats, Xenobiotica, 2014, 44, 11, 1014

    CrossRef

  18. 18
    Blaire E. Burman, Paul Y. Kwo, Kris V. Kowdley, Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity, Hepatology International, 2014, 8, 3, 352

    CrossRef

  19. 19
    William L. Irving, Daniel Rupp, C. Patrick McClure, Lwin Mar Than, Andrew Titman, Jonathan K. Ball, Eike Steinmann, Ralf Bartenschlager, Thomas Pietschmann, Richard J.P. Brown, Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region, Antiviral Research, 2014, 110, 52

    CrossRef

  20. 20
    Åsa Rosenquist, Bertil Samuelsson, Per-Ola Johansson, Maxwell D. Cummings, Oliver Lenz, Pierre Raboisson, Kenny Simmen, Sandrine Vendeville, Herman de Kock, Magnus Nilsson, Andras Horvath, Ronald Kalmeijer, Guy de la Rosa, Maria Beumont-Mauviel, Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor, Journal of Medicinal Chemistry, 2014, 57, 5, 1673

    CrossRef

  21. 21
    Sarah Tischer, Robert J. Fontana, Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting, Journal of Hepatology, 2014, 60, 4, 872

    CrossRef

  22. 22
    Isabel Fofana, Nikolaus Jilg, Raymond T. Chung, Thomas F. Baumert, Entry inhibitors and future treatment of hepatitis C, Antiviral Research, 2014, 104, 136

    CrossRef

  23. 23
    Natalia Lorna Laufer, Jürgen Kurt Rockstroh, Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV, Expert Review of Anti-infective Therapy, 2014, 12, 2, 157

    CrossRef

  24. You have free access to this content24
    Raymond Schinazi, Philippe Halfon, Patrick Marcellin, Tarik Asselah, HCV direct-acting antiviral agents: the best interferon-free combinations, Liver International, 2014, 34,
  25. You have free access to this content25
    Mitchell L. Shiffman, Yves Benhamou, HCV F1/F2 patients: treat now or continue to wait, Liver International, 2014, 34,
  26. 26
    Kian Bichoupan, Douglas T. Dieterich, Hepatitis C in HIV-Infected Patients: Impact of Direct-Acting Antivirals, Drugs, 2014, 74, 9, 951

    CrossRef

  27. 27
    Imran Shahid, Waleed Hassan ALMalki, Muhammad Hassan Hafeez, Sajida Hassan, Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies, Critical Reviews in Microbiology, 2014, 1

    CrossRef

  28. 28
    Mitchell L. Shiffman, Hepatitis C virus therapy in the direct acting antiviral era, Current Opinion in Gastroenterology, 2014, 30, 3, 217

    CrossRef

  29. 29
    JS Au, PJ Pockros, Novel Therapeutic Approaches for Hepatitis C, Clinical Pharmacology & Therapeutics, 2014, 95, 1
  30. 30
    Tae Hun Kim, June Sung Lee, Recent Advancement in the Treatment of Chronic Hepatitis C, Korean Journal of Medicine, 2014, 86, 5, 563

    CrossRef

  31. 31
    Eric J Lawitz, Fernando E Membreno, Response-guided therapy in patients with genotype 1 hepatitis C virus: Current status and future prospects, Journal of Gastroenterology and Hepatology, 2014, 29, 8
  32. You have free access to this content32
    M. H. Miller, K. Agarwal, A. Austin, A. Brown, S. T. Barclay, P. Dundas, G. M. Dusheiko, G. R. Foster, R. Fox, P. C. Hayes, C. Leen, C. Millson, S. D. Ryder, J. Tait, A. Ustianowski, J. F. Dillon, Review article: 2014 UK consensus guidelines – hepatitis C management and direct-acting anti-viral therapy, Alimentary Pharmacology & Therapeutics, 2014, 39, 12
  33. 33
    Kentaro Matsuura, Tsunamasa Watanabe, Yasuhito Tanaka, Role of IL28B for chronic hepatitis C treatment toward personalized medicine, Journal of Gastroenterology and Hepatology, 2014, 29, 2
  34. 34
    Shuhei Nishiguchi, Yoshiyuki Sakai, Makoto Kuboki, Satoshi Tsunematsu, Yasuhisa Urano, Wataru Sakamoto, Yasuhiro Tsuda, Gerhard Steinmann, Masao Omata, Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection, Liver International, 2014, 34, 1
  35. You have free access to this content35
    Tarik Asselah, Patrick Marcellin, Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir, Liver International, 2014, 34,
  36. 36
    Michael P. Manns, John M. Vierling, Bruce R. Bacon, Savino Bruno, Oren Shibolet, Yaacov Baruch, Patrick Marcellin, Luzelena Caro, Anita Y.M. Howe, Christine Fandozzi, Jacqueline Gress, Christopher L. Gilbert, Peter M. Shaw, Michael P. Cooreman, Michael N. Robertson, Peggy Hwang, Frank J. Dutko, Janice Wahl, Niloufar Mobashery, The Combination of MK-5172, Peginterferon, and Ribavirin Is Effective in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection Without Cirrhosis, Gastroenterology, 2014, 147, 2, 366

    CrossRef

  37. 37
    Parth J Parekh, Mitchell L Shiffman, The role of interferon in the new era of hepatitis C treatments, Expert Review of Gastroenterology & Hepatology, 2014, 8, 6, 649

    CrossRef

  38. You have free access to this content38
    Valérie Martel-Laferrière, Douglas T. Dieterich, Treating HCV in HIV 2013: on the cusp of change, Liver International, 2014, 34,
  39. 39
    Danushka Kumara Wijesundara, Yang Xi, Charani Ranasinghe, Unraveling the Convoluted Biological Roles of Type I Interferons in Infection and Immunity: A Way Forward for Therapeutics and Vaccine Design, Frontiers in Immunology, 2014, 5,

    CrossRef

  40. 40
    Timothy A. Stammers, René Coulombe, Martin Duplessis, Gulrez Fazal, Alexandre Gagnon, Michel Garneau, Sylvie Goulet, Araz Jakalian, Steven LaPlante, Jean Rancourt, Bounkham Thavonekham, Dominik Wernic, George Kukolj, Pierre L. Beaulieu, Anthranilic acid-based Thumb Pocket 2 HCV NS5B polymerase inhibitors with sub-micromolar potency in the cell-based replicon assay, Bioorganic & Medicinal Chemistry Letters, 2013, 23, 24, 6879

    CrossRef

  41. 41
    Jennifer J. Kiser, James R. Burton, Gregory T. Everson, Drug–drug interactions during antiviral therapy for chronic hepatitis C, Nature Reviews Gastroenterology & Hepatology, 2013, 10, 10, 596

    CrossRef

  42. 42
    Jürgen K Rockstroh, Sanjay Bhagani, Managing HIV/hepatitis C co-infection in the era of direct acting antivirals, BMC Medicine, 2013, 11, 1, 234

    CrossRef

  43. 43
    Mohamed A Daw, Hana A Elasifer, Aghnaya A Dau, Mohamed Agnan, The role of hepatitis C virus genotyping in evaluating the efficacy of INF-based therapy used in treating hepatitis C infected patients in Libya, Virology Discovery, 2013, 1, 1, 3

    CrossRef